Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8510 Monotherapy in Anti-retroviral-naïve HIV-1
NCT05700734Phase 1Withdrawn
- Sponsor
- Merck & Co.
- Start
- Apr 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of mk-8510 in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by Merck & Co. Primary endpoints: Change from Baseline in Plasma HIV-1 RNA, Percentage of Participants Who Experience an Adverse Event at 36 days and 1 more. Planned start Apr 2023; status: withdrawn.
02
Drugs
mk-8510
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05700734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05700734.